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Background: Hyperthyroidism may complicate preexisting cardiac disease
or may cause cardiac complications in individuals with structurally normal
hearts defining cardiothyrotoxicosis. They are underdiagnosed, due to its low
occurrence in series from Africa. The aim of this study is to assess the inci-
dence, the demographic data, diagnostic features and etiological aspects of
cardiothyrotoxicosis among hyperthyroidisms.
Methods and results: Since August 2004 we have prospectively enrolled
348 patients with hyperthyroidism in cardiology and endocrinology departments
in 03 hospitals of Marrakech, we have divided them into 2 groups: 58 cases with
cardiothyrtoxicosis (goup I) and 290 with only hyperthyroidism (group II).
Cardiothyrotoxicosis was observed with an incidence of 16.6%. The mean
age was respectively of 45.5±13.3 versus 33.8±11.4 years (p<10-6). Cardiothy-
rotoxicosis was related to multinodular goiters (30 cases, 52%), while the prin-
cipal cause of hyperthyroidism was toxic adenoma (122 cases, 42%). The
clinical profiles of cardiothyrotoxicosis were dominated by heart failure in
44 cases (75%) and atrial fibrillation in 33 cases (57%). The other modes of pre-
sentation were: The atrial flutter in 02 cases, ventricular extrasystoli (trigeminism)
in 02 cases, second auriculoventricular block in 02 cases, dilated myocardiopathy
in 10 cases, coronary heart disease occurred in 05 cases and severe mitral regurgi-
tation in 02 cases. Treatment requires nessecarily return to euthyroidism.
Conclusion: This study confirms the relative frequency of cardiothyro-
toxcosis, the proportionally weak place of Basedow disease among hyper-
thyroidysm causes and the involvement of associated cardiac disease and
higher age in cardiothyrotoxicosis.
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Context: Dilated Cardiomyopathy (DCM) is familial in at least 30% of
cases, usually with autosomal dominant inheritance, and underlying genes/
mutations are increasingly identified. Familial DCM is characterized by age-
related penetrance, that means that the cardiac expression of the disease is
usually absent for a long period and progressively appears with advanced age,
usually after 20 years of age.
Aim: Study the impact of ACE inhibitors (ACEi) in subjects who carry a
mutation (leading to a genetic form of heart failure) but have not yet devel-
oped DCM (cardiac expression).
Design: This is a multicentre European double-blind randomized and
controlled trial with perindopril or placebo in the context of a European
consortium “INHERITANCE” (FP7 European Union, HEALTH-2009-2.4.2-3,
Grant agreement n° 241924). The PRECARDIA trial was recently approved
by the Head of medicines Agencies in Europe (HMA) and by AFSSAPS in
France. We plan to enroll 200 participants from 7 European centres/countries.
Follow-up duration is 3 years after inclusion. Primary Endpoint is a composite
end-point: occurrence of DCM or deterioration of LV end diastolic diameter/
volume or Ejection fraction (echocardiographic or magnetic resonance
imaging). Secondary Endpoints are related to the evolution of other echocar-
diographic parameters or hormonal biomarkers (including Mid-Regional pro-
Adrenomedullin).
Expected results: If the hypothesis is confirmed, and as a consequence,
the knowledge derived from basic research (genes identification in DCM) will
be translated into clinical practice (early identification of subjects at high risk
of developing heart failure through predictive genetic testing) with the devel-
opment of new therapeutic management (early ACEi) that will help to
decrease the morbidity and mortality associated with the disease. This will
constitute a paradigm of the development of preventive medicine thanks to the
development of genetics in the cardiovascular field.
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Objectives: We sought to analyze B-type natriuretic peptide (BNP)/tro-
ponin I (TnI) ratio and TnI kinetics to differentiate apical ballooning syn-
drome (ABS) from acute coronary syndrome (ACS).
Methods: In 62 ABS, TnI and BNP measurements were collected prospec-
tively and compared to 90 patients with anterior ST-segment elevation myo-
cardial infarctions (STEMI) (n=47) and anterior non-STEMI (n=43). 
Results: In case of persistent ST-segment elevation, BNP/TnI ratio above
165 can identify ABS with accuracy (sensitivity: 95%, specificity: 98%). In
the absence of persistent ST-segment elevation, a ratio above 515 can identify
ABS (sensitivity: 57%, specificity: 86%). Decreasing TnI profile was found
more in ABS than in ACS. TnI peak occurred earlier in ABS than in ACS. A
normal TnI on patient admission may exclude ABS.
Conclusions: Analysis of BNP and TnI provides a simple, non-invasive
method to differentiate ABS from ACS.
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